Review of medical prevention of vasospasm after aneurysmal subarachnoid hemorrhage: a problem of neurointensive care
- PMID: 11220367
- DOI: 10.1097/00006123-200102000-00001
Review of medical prevention of vasospasm after aneurysmal subarachnoid hemorrhage: a problem of neurointensive care
Abstract
Cerebral vasospasm remains a devastating medical complication of aneurysmal subarachnoid hemorrhage (SAH). It is associated with high morbidity and mortality rates, even after the aneurysm has been secured surgically or radiologically. A great deal of experimental and clinical research has been conducted in an effort to find ways to prevent this complication. The literature includes extensive coverage of in vivo animal model studies of SAH and vasospasm. These experimental studies have contributed to tremendous advances in the understanding of the mechanisms leading to cerebral vasospasm. Most of the experimental settings, however, have demonstrated varying levels of ability to predict accurately what occurs in human SAH. Therefore, although animal models have been developed to test new therapies, most of the treatment effects have been shown to be less compelling when trials have been conducted in clinical settings. The interpretation of current literature is complicated further by the imprecise estimation of the incidence of cerebral vasospasm, which is due to various degrees of clinical expression, ranging from the absence of symptoms in the presence of increased blood flow velocities at transcranial Doppler or vessel diameter reduction at angiography to neurological manifestations of severe ischemic deficits. In addition, a change over time in the incidence pattern of human SAH and vasospasm, possibly related to improved surgical techniques and overall patient management, may have occurred. This topic review collects the relevant literature on clinical trials investigating prophylactic therapies for cerebral vasospasm in patients with aneurysmal SAH and emphasizes the need for large clinical trials to confirm the results derived from clinical experience. In addition, it points out some experimental therapies that may hold promise in future clinical trials to prevent the occurrence of vasospasm.
Similar articles
-
Prediction of cerebral vasospasm in patients presenting with aneurysmal subarachnoid hemorrhage: a review.Neurosurgery. 2005 Apr;56(4):633-54; discussion 633-54. doi: 10.1227/01.neu.0000156644.45384.92. Neurosurgery. 2005. PMID: 15792502 Review.
-
A review of current and future medical therapies for cerebral vasospasm following aneurysmal subarachnoid hemorrhage.Neurosurg Focus. 2006 Sep 15;21(3):E9. doi: 10.3171/foc.2006.21.3.9. Neurosurg Focus. 2006. PMID: 17029348 Review.
-
Vasospasm probability index: a combination of transcranial doppler velocities, cerebral blood flow, and clinical risk factors to predict cerebral vasospasm after aneurysmal subarachnoid hemorrhage.J Neurosurg. 2007 Dec;107(6):1101-12. doi: 10.3171/JNS-07/12/1101. J Neurosurg. 2007. PMID: 18077946
-
Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study.J Neurosurg. 2016 Jan;124(1):51-8. doi: 10.3171/2014.12.JNS13846. Epub 2015 Jul 10. J Neurosurg. 2016. PMID: 26162034
-
Role of bedside microdialysis in the diagnosis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage.J Neurosurg. 2001 May;94(5):740-9. doi: 10.3171/jns.2001.94.5.0740. J Neurosurg. 2001. PMID: 11354405 Clinical Trial.
Cited by
-
Efficacy of combined intravenous plus intrathecal nimodipine administration in patients with severe cerebral vasospasm post‑aneurysmal subarachnoid hemorrhage: A retrospective cohort study.Med Int (Lond). 2022 Dec 16;3(1):3. doi: 10.3892/mi.2022.63. eCollection 2023 Jan-Feb. Med Int (Lond). 2022. PMID: 36699659 Free PMC article.
-
Impact of percutaneous transluminal angioplasty for treatment of cerebral vasospasm on subarachnoid hemorrhage patient outcomes.Neurocrit Care. 2011 Aug;15(1):28-33. doi: 10.1007/s12028-010-9499-y. Neurocrit Care. 2011. PMID: 21360234
-
Sudden death and cervical spine: A new contribution to pathogenesis for sudden death in critical care unit from subarachnoid hemorrhage; first report - An experimental study.J Craniovertebr Junction Spine. 2017 Jan-Mar;8(1):33-38. doi: 10.4103/0974-8237.199870. J Craniovertebr Junction Spine. 2017. PMID: 28250634 Free PMC article.
-
High-dose bosentan in the prevention and treatment of subarachnoid hemorrhage-induced cerebral vasospasm: an open-label feasibility study.Neurocrit Care. 2007;7(3):194-202. doi: 10.1007/s12028-007-0070-4. Neurocrit Care. 2007. PMID: 17901934 Clinical Trial.
-
Current practices of triple-H prophylaxis and therapy in patients with subarachnoid hemorrhage.Neurocrit Care. 2011 Feb;14(1):24-36. doi: 10.1007/s12028-010-9437-z. Neurocrit Care. 2011. PMID: 20838932
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical